B. Riley Initiates Coverage on Immunic (NASDAQ:IMUX)

Analysts at B. Riley began coverage on shares of Immunic (NASDAQ:IMUX) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $6.00 price target on the stock. B. Riley’s price target suggests a potential upside of 325.53% from the company’s current price.

Other equities analysts also recently issued research reports about the company. StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. Piper Sandler restated an “overweight” rating and set a $28.00 price objective on shares of Immunic in a report on Tuesday, July 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Immunic presently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $1.41 on Tuesday. Immunic has a one year low of $0.95 and a one year high of $1.92. The firm has a market capitalization of $127.01 million, a P/E ratio of -0.77 and a beta of 1.76. The company’s fifty day moving average is $1.31 and its two-hundred day moving average is $1.30.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. During the same period in the previous year, the company earned ($0.54) EPS. On average, sell-side analysts forecast that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Institutional investors have recently bought and sold shares of the stock. Gratus Capital LLC boosted its holdings in shares of Immunic by 15.1% in the 4th quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock valued at $2,912,000 after purchasing an additional 254,999 shares during the last quarter. Sierra Summit Advisors LLC purchased a new stake in Immunic during the fourth quarter valued at about $487,000. Summit Trail Advisors LLC purchased a new stake in Immunic during the first quarter valued at about $25,000. Vanguard Group Inc. increased its stake in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the last quarter. Finally, BVF Inc. IL purchased a new position in shares of Immunic in the 1st quarter worth about $11,752,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.